202 search results for: Pathophysiology
Heterogeneous Presentation and Diagnosis in Bullous Pemphigoid
Dr. Donna Culton describes the heterogeneous presentation and diagnosis of bullous pemphigoid at EADV 2025
Both Clinical and Subclinical Disease Control Are Important to Achieve Disease Modification in AD
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Eric Simpson explains how both clinical and subclinical disease control are critical for achieving true disease modification in atopic dermatitis, emphasizing the role of biomarkers in predicting long-term outcomes and guiding treatment decisions.
Understanding Barriers to Advanced Systemic Therapy in AD
Dr. Jean-David Bouaziz highlights a study describing barriers to initiating advanced systemic therapy for AD at EADV 2025
Navigating Complex Definitions: Early Intervention and Disease Modification in Atopic Dermatitis
Dr. Amy Paller discusses the evolving concepts of early intervention and disease modification in AD and describes potential biomarkers of subclinical control at EADV 2025.
KOL Video Interview – Dr Paula Luna
In this exclusive video interview, Dr Paula Luna discusses how disease modification can be defined in AD and how IgE may be used as a biomarker in AD.
The Shared Path: Type 2 Inflammation As a Driver of Chronic Itch
Professor Matthias Augustin highlights the role of type 2 inflammation in chronic itch across distinct pruritic skin diseases and the cumulative burden of chronic itch and skin lesions in PN.
How Can FeNO Measurement Improve Severe Asthma Management?
Join Dr. Miguel Lanz as he explains the clinical utility of FeNO as a biomarker of severe asthma.
Translating the Science of CSU: From Pathogenesis to Patient Outcomes
Watch as Drs. Michihiro Hide, Marta Ferrrer, and Ana M. Giménez-Arnau discuss chronic spontaneous urticaria (CSU) and highlight the unmet needs, importance of disease control, and emerging therapies.
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD
In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression
Blisters and Beyond: Autoimmunity Meets Type 2 Inflammation in Bullous Pemphigoid
Join Dr. Victoria Werth in exploring the clinical presentation of BP and how type 2 inflammation contributes to the development of disease signs and symptoms
The Cycle of Inflammation in Adult Asthma
Explore the role of chronic type 2 inflammation in the cycle of exacerbations and worsening lung function in patients with asthma.
Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13
Dr. Reynold Panettieri discusses how IL-4 and IL-13 drive airway remodeling in type 2 asthma.
